Plus   Neg

Moderna Begins Phase 2/3 Study Of COVID-19 Vaccine Candidate In Children

Moderna Inc. (MRNA) said the first participants have been dosed in the phase 2/3 study of mRNA-1273, the company's vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The company plans to enroll approximately 6,750 pediatric participants in the U.S. and Canada ages 6 months to less than 12 years.

Moderna COVID-19 Vaccine is authorized for use under an Emergency Use Authorization for active immunization to prevent COVID-19 in individuals 18 years of age and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT